Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2024 | Story André Damons | Photo André Damons
Dr Innocensia Mangoato
Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. Here she is with her supervisor and mentor Prof Motlalepula Matsabisa, Director of the University of the Free State (UFS) Department of Pharmacology.

A lecturer and researcher from the University of the Free State (UFS) Department of Pharmacology hopes her research into the use of cannabis in reversing anticancer drug resistance is a step forward into treating various cancers especially in Southern Africa.

Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with the degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. She started her career as a research scientist in the area of African traditional medicines in 2018 and her research received both national and international recognition.

“It’s an amazing (feeling to graduate today). My PhD journey was smooth and beautiful and with mentorship of Prof (Motlalepula) Matsabisa, who groomed me well, I did not shed a tear,” said Dr Mangoato. Dr Gudrun S Ulrich-Merzenich from the University of Bonn in Germany, was her co-supervisor with Prof Matsabisa.

According to the graduation programme, Dr Mangoato, Lecturer and Researcher in the UFS Department of Pharmacology, with her thesis titled Investigating the anticancer and possible resistant reversal effects of cannabis sativa l. extracts in cervical cancer cell lines and modulation of ABC transporters comprehensively explored the therapeutic potential of Cannabis sativa L. in overcoming drug resistance in cervical cancer using in vitro and network pharmacology approaches.

A step forward for treating various cancers

The research looked at the chemical fingerprints and pharmacological targets of C. sativa L. extracts, highlighting its antiproliferative properties against normal non-cancerous cells, cervical cancer cells and the cisplatin-resistant cervical cancer cells. Through PCR analysis, distinct gene expression profiles were identified, revealing the potential effects of combination treatments to counteract cisplatin resistance by downregulating genes associated with drug transporters and crucial signalling pathways. This work provides valuable insights into innovative therapeutic strategies for improving cervical cancer treatment, highlighting new avenues for overcoming resistance and enhancing treatment efficacy though the possible use of plant extracts.

“I hope my research takes a step forward in treating various cancers – especially gynaecology cancers in the Southern Hemisphere in Africa. Hopefully the research can later transcend into clinical trials and hopefully influence more policymakers. We also hope to further develop cannabis to be used as an adjuvant therapy for those drugs that are failing to treat cancer,” says Dr Mangoato, who was the recipient of the Women in Science Master’s Student in 2018.

Her graduation was also a proud moment for Prof Matsabisa, an expert in traditional African medicine, who was like a father to her during her studies. “Prof identified me from my honours degree and walked this journey with me. He has been a great mentor, a father and an amazing supervisor.”

Dr Mangoato says she will for now focus on research only and helping and monitoring upcoming researchers, especially female researchers as there is a scarcity of them her field. 

News Archive

Death may come in adorable little packages
2015-03-23

The main host of the Lassa virus is the Natal Mulimammate mouse.

Photo: Supplied

Postdoctoral researcher, Abdon Atangana, of the Institute for Groundwater Studies at the university recently published an article online about the Lassa Haemorrhagic fever in the Natural Computing Applications Forum. In addition to the terminal transmissible sickness recognised as Ebola haemorrhagic fever, there is another strain called Lassa haemorrhagic fever.

The disease is classified under the arenaviridae virus family. The first outbreaks of the disease were observed in Nigeria, Liberia, Sierra Leone, and the Central African Republic. However, it was first described in 1969 in the town of Lassa, in Borno State, Nigeria.

The main host of the Lassa virus is the Natal Mulimammate mouse, an animal indigenous to most of Sub-Saharan Africa. The contamination in humans characteristically takes place through exposure to animal excrement through the respiratory or gastrointestinal tracts.

Mouthfuls of air containing tiny particle of infective material are understood to be the most noteworthy way of exposure. It is also possible to acquire the infection through broken skin or mucous membranes that are directly exposed to the infective material.

“The aim of my research was to propose a novel mathematical equation used to describe the spread of the illness amongst pregnant women in West Africa. To achieve this, I used my newly-proposed derivative with fractional order called beta-derivative. Since none of the commonly used integral transform could be used to derive the solution of the proposed model, I proposed a new integral transform called Atangana-Transform, and used it, together with some iterative technique, to derive the solution of the model.

“My numerical simulations show that the disease is as deadly amongst pregnant women as Ebola,” Abdon said.

Abdon’s research was submitted to one of Springer’s top-tier journals with an impact factor 1.78. The paper was accepted and published February 2015.

Read more about Abdon’s research.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept